📇 Rhumatologue · PARIS CEDEX 15 · (75) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Auteur de référence en rhumatologie
30 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
75
75 articles ont été cités au moins 75fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
25 401
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
646
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
292
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Necker-Enfants Malades · Inserm · Université Paris Cité
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
2026ArticleBritish Journal of Dermatology
Mepyramine targets mutant Nav1.7 channels to relieve pain and erythema in primary erythromelalgia patients
2025ArticleFrontiers in Medicine
Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression
2025ArticleBlood Cancer Journal
A proposal for a new pathogenesis-guided classification for inherited epidermal differentiation disorders
2025ArticleBritish Journal of Dermatology
[Letter to the editor] Dazukibart for the treatment of severe TIF1γ ‐positive juvenile dermatomyositis
2025ArticleJournal of the European Academy of Dermatology and Venereology
Immune response and clinical severity are shaped by skin-adapted Staphylococcus aureus in chronically infected patients
2025ArticleScience Translational Medicine
Management of congenital ichthyoses: guidelines of care: Part two: 2024 update
2025ArticleBritish Journal of Dermatology
Management of congenital ichthyoses: guidelines of care: Part one: 2024 update
2025ArticleBritish Journal of Dermatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU CUP SITE NECKER ENFANTS MALADES
149 R DE SEVRES, 75743 PARIS CEDEX 15
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Journal of experimental medicine · 2024
UNC93B1 is a transmembrane domain protein mediating the signaling of endosomal Toll-like receptors (TLRs). We report five families harboring rare missense substitutions (I317M, G325C, L330R, R466S, and R525P) in UNC93B1 causing systemic lupus erythematosus (SLE) or chilblain lupus (CBL) as either autosomal dominant or autosomal recessive traits. As for a D34A mutation causing murine lupus, we recorded a gain of TLR7 and, to a lesser extent, TLR8 activity with the I317M (in vitro) and G325C (in vitro and ex vivo) variants in the context of SLE. Contrastingly, in three families segregating CBL, the L330R, R466S, and R525P variants were isomorphic with respect to TLR7 activity in vitro and, for R525P, ex vivo. Rather, these variants demonstrated a gain of TLR8 activity. We observed enhanced interaction of the G325C, L330R, and R466S variants with TLR8, but not the R525P substitution, indicating different disease mechanisms. Overall, these observations suggest that UNC93B1 mutations cause monogenic SLE or CBL due to differentially enhanced TLR7 and TLR8 signaling.
The Journal of allergy and clinical immunology · 2024
The Journal of experimental medicine · 2024
Human inborn errors of thymic T cell tolerance underlie the production of autoantibodies (auto-Abs) neutralizing type I IFNs, which predispose to severe viral diseases. We analyze 131 female patients with X-linked dominant incontinentia pigmenti (IP), heterozygous for loss-of-function (LOF) NEMO variants, from 99 kindreds in 10 countries. Forty-seven of these patients (36%) have auto-Abs neutralizing IFN-α and/or IFN-ω, a proportion 23 times higher than that for age-matched female controls. This proportion remains stable from the age of 6 years onward. On imaging, female patients with IP have a small, abnormally structured thymus. Auto-Abs against type I IFNs confer a predisposition to life-threatening viral diseases. By contrast, patients with IP lacking auto-Abs against type I IFNs are at no particular risk of viral disease. These results suggest that IP accelerates thymic involution, thereby underlying the production of auto-Abs neutralizing type I IFNs in at least a third of female patients with IP, predisposing them to life-threatening viral diseases.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Rheumatology (Oxford, England) · 2026 · Journal Article
Moreau TRJ, Bondet V, Veldkamp SR, Bletry D, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · Letter
Fournier B, Sugrue J, Welfringer-Morin A, Moreau TRJ, et al.
Nature medicine · 2025 · Published Erratum
Bal E, Park HS, Belaid-Choucair Z, Kayserili H, et al.
Haematologica · 2025 · Journal Article
Rossignol J, Georgin-Lavialle S, Canioni D, Beganovic O, et al.
Frontiers in medicine · 2025 · Journal Article
Ducrocq M, Penalba V, Castillo L, Bodemer C, et al.
Science translational medicine · 2025 · Journal Article
Jamet A, Fu X, Dietrich C, Bellon N, et al.
EMBO molecular medicine · 2025 · Journal Article
Morin G, Garneau AP, Bouzakher N, Ségot L, et al.
The Journal of experimental medicine · 2024 · Journal Article
Rosain J, Le Voyer T, Liu X, Gervais A, et al.
Journal of the American Academy of Dermatology · 2024 · Letter
Bellon N, Bataille P, Bonigen J, Charbit-Henrion F, et al.
The Journal of investigative dermatology · 2024 · Journal Article
Berthy C, Gagnoux-Palacios L, Madrange M, Bodemer C, et al.
The British journal of dermatology · 2026 · Journal Article
Bellon N, Clerc A, Bataille P, Lambe C, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · Journal Article
Miao Y, Beauchet A, Piram M, McPherson T, et al.
The British journal of dermatology · 2026 · Journal Article
Mayrand L, Bonigen J, Marquant F, Schinkel N, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · Letter
Seyler M, Bodemer C, Hadj-Rabia S
The British journal of dermatology · 2025 · Journal Article
Boudhabhay I, Bellon N, Avramescu M, Bataille P, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2025 · Letter
Bonigen J, Charbit-Henrion F, Leclerc-Mercier S, Rosenthal JM, et al.
The British journal of dermatology · 2024 · Journal Article
Bettuzzi T, Welfringer-Morin A, Ingen-Housz-Oro S, Bataille P, et al.
Orphanet journal of rare diseases · 2026 · Journal Article
Linertová R, Péntek M, Rodríguez-Díaz B, Bodemer C, et al.
Italian journal of pediatrics · 2024 · Journal Article
El Hachem M, Diociaiuti A, Zambruno G, Samela T, et al.
The British journal of dermatology · 2024 · Journal Article
El Hachem M, De Marco R, Soria de Francisco JM, Audouze A, et al.
Clinical, cosmetic and investigational dermatology · 2024 · Journal Article
Alheggi A, Alfahhad A, Bukhari A, Bodemer C
Italian journal of pediatrics · 2024 · Journal Article
El Hachem M, Diociaiuti A, Zambruno G, Samela T, et al.
Dermatology (Basel, Switzerland) · 2025 · Journal Article
Nouwen AEM, Ragamin A, Knol MJ, Ott H, et al.
The British journal of dermatology · 2025 · Journal Article
El Hachem M, Caldaro T, Lara-Corrales I, Pope E, et al.
Pediatrics · 2026 · Journal Article
Jaume L, Schmartz S, Welfringer-Morin A, Delacourt C, et al.
The British journal of dermatology · 2025 · Journal Article
Murrell DF, Bodemer C, Bruckner AL, Cunningham T, et al.
The Journal of pathology · 2025 · Journal Article
Al Youssef C, Alkobtawi M, Safi R, Chanal J, et al.
The Journal of experimental medicine · 2024 · Journal Article
David C, Arango-Franco CA, Badonyi M, Fouchet J, et al.
The British journal of dermatology · 2025 · Journal Article
Murrell DF, Bodemer C, Bruckner AL, Cunningham T, et al.
Additional file 1: of Burden of albinism: development and validation of a burden assessment tool
French and English (US) versions of the BoA questionnaire. (XLSX 10 kb)
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)
Abstract Background Epidermolysis bullosa (EB) is a rare genetic disorder that manifests as blistering and/or skin erosion. There is no approved treatment for EB; current standard of care consists of wound and pain manag
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)
Abstract Background Epidermolysis bullosa (EB) is a rare genetic disorder that manifests as blistering and/or skin erosion. There is no approved treatment for EB; current standard of care consists of wound and pain manag
Health-related quality of life in adults with epidermolysis bullosa: a cross-sectional study in seven European countries using EQ-5D-5L
Abstract Background Epidermolysis bullosa (EB) is a rare genetic disorder that causes extreme skin fragility, chronic pain, and functional impairment, with major psychosocial and economic consequences. Health-related qua
Burden of albinism: development and validation of a burden assessment tool
Abstract Background Albinism comprises a group of autosomal recessive diseases that are characterized by poor vision and a variable hypopigmentation phenotype. A comprehensive literature review showed that no tool can as
Additional file 1: of Burden of albinism: development and validation of a burden assessment tool
French and English (US) versions of the BoA questionnaire. (XLSX 10 kb)
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Allergy · 2025 · Letter
Puel M, Rossignol J, Devin C, Madrange M, et al.
The British journal of dermatology · 2024 · Journal Article
Bettuzzi T, Welfringer-Morin A, Ingen-Housz-Oro S, Bataille P, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2024 · Journal Article
Bataille P, Lebrun-Vignes B, Bettuzzi T, Ingen-Housz-Oro S, et al.
The Journal of allergy and clinical immunology · 2024 · Journal Article
Polivka L, Madrange M, Bulai-Livideanu C, Barete S, et al.